Research
Hormonal
GLP1-RA therapy appears safe and effective in patients with IBD.
GLP1-RA may be considered a treatment option for managing IBD.
StrongSupportsmedium confidence
GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.
Why this rating
The study involved a retrospective analysis of 120 patients.
Source
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease
Scott R. Anderson et al. · The American Journal of Gastroenterology · 2024
DOI 10.14309/ajg.0000000000003208
cohort · n=120Cited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →